Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Plunkett Research, Ltd.
$99.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AstraZeneca PLC and Isis Pharmaceuticals Inc Start Strategic Collaboration


Tuesday, 11 Dec 2012 07:05am EST 

AstraZeneca PLC announced that it has launched a strategic collaboration with Isis Pharmaceuticals Inc for the discovery and development of new generation antisense therapeutics against five cancer targets, which includes a license to develop and commercialize ISIS-STAT3Rx, a drug Isis Pharmaceuticals is evaluating in an early clinical trial in patients with advanced lymphomas. The strategic alliance aims to apply AstraZeneca's experience in developing personalized medicines to enhance the drug discovery and development process for four research programs in the oncology area and to aid in the development of ISIS-STAT3Rx for patient populations that could benefit from inhibition of STAT3, a protein that drives cancer growth. Under the agreement, Isis will receive from AstraZeneca USD 31 million in upfront and near term payments, comprising a USD 25 million payment on signing followed by USD 6 million payment in the second quarter of 2013 assuming the research program is continuing. Isis has granted AstraZeneca an exclusive license to develop and commercialize ISIS-STAT3Rx and a pre-clinical program as well as an option to license products developed under a separate research program. AstraZeneca will be responsible for all further development and commercialization. Isis is also eligible to receive downstream development and approval payments, license fees for research program targets as well as royalties on sales from products that are successfully commercialized. 

Company Quote

4426.0
36.0 +0.82%
22 Jul 2014